Neurimmune Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
68
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
1
Neurimmune General Information
Description
Operator of a biopharmaceutical company intended to translate human immune memory into antibody therapeutics. The company translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates.
Contact Information
Website
www.neurimmune.comCorporate Office
- Wagistrasse 18
- 10th floor
- 8952 Zurich
- Switzerland
Corporate Office
- Wagistrasse 18
- 10th floor
- 8952 Zurich
- Switzerland
Neurimmune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Accelerator/Incubator | 01-Jan-2011 | Completed | Generating Revenue | |||
| 1. Spin-Off | 14-Nov-2006 | Completed | Generating Revenue |
Neurimmune Patents
Neurimmune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016205988-A1 | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof | Inactive | 09-Jan-2015 | ||
| CA-2973040-A1 | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof | Inactive | 09-Jan-2015 | ||
| EP-3242683-A1 | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof | Inactive | 09-Jan-2015 | ||
| US-20170369592-A1 | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof | Inactive | 09-Jan-2015 | ||
| WO-2016110598-A1 | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof | Inactive | 09-Jan-2015 | C07K16/40 |
Neurimmune Signals
Neurimmune Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| University of Zürich | University | Minority |
Neurimmune Investments (4)
Neurimmune’s most recent deal was a Later Stage VC with NovaGo Therapeutics for . The deal was made on 31-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NovaGo Therapeutics | 31-Aug-2026 | Later Stage VC | Drug Discovery | ||
| NovaGo Therapeutics | 04-Mar-2019 | Early Stage VC | Drug Discovery | ||
| AL-S Pharma | 30-Jan-2018 | Early Stage VC | Drug Discovery | ||
| AL-S Pharma | 07-Dec-2016 | Early Stage VC | Drug Discovery |
Neurimmune FAQs
-
When was Neurimmune founded?
Neurimmune was founded in 2006.
-
Where is Neurimmune headquartered?
Neurimmune is headquartered in Zurich, Switzerland.
-
What is the size of Neurimmune?
Neurimmune has 68 total employees.
-
What industry is Neurimmune in?
Neurimmune’s primary industry is Drug Discovery.
-
Is Neurimmune a private or public company?
Neurimmune is a Private company.
-
What is Neurimmune’s current revenue?
The current revenue for Neurimmune is .
-
Who are Neurimmune’s investors?
University of Zürich has invested in Neurimmune.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process